Active Ingredient History
Meropenem (generic name: meropenem hydrate) is a carbapenem antibiotic for injection showing a strong antibacterial activity to a wide range of bacteria strains from Gram-positive bacteria, Gram-negative bacteria to anaerobic bacteria. It is used as single agent therapy for the treatment of the following infections: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci. This drug also used in case of Intra-abdominal Infections for the treatment complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. In addition is used the treatment of bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (b-lactamase and non-b-lactamase-producing isolates), and Neisseria meningitides. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2 and 4 of Staphylococcus aureus. Meropenem has significant stability to hydrolysis by β-lactamases, both penicillinases and cephalosporinases produced by Gram-positive and Gram-negative bacteria. Meropenem should not be used to treat methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant Staphylococcus epidermidis (MRSE). Meropenem product with such superior effectiveness and safety has been approved for marketing by 100 countries or more in the world (as of March 2004) since its first launch in Italy in 1994. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Appendicitis (approved 1996)
Meningitis, Bacterial (approved 1996)
Staphylococcal Skin Infections (approved 1996)
Abdomen, Acute (Phase 3)
Abdominal Abscess (Phase 3)
Abdominal Pain (Phase 3)
Abscess (Phase 3)
Appendicitis (Phase 3)
Ascites (Phase 2/Phase 3)
Bacteremia (Phase 4)
Bacterial Infections (Phase 4)
Blood-Borne Infections (Phase 3)
Bronchiectasis (Phase 4)
Carbapenems (Phase 4)
Cellulitis (Phase 3)
Central Nervous System Infections (Phase 4)
Clinical Trial (Phase 4)
Critical Illness (Phase 4)
Cross Infection (Phase 2)
Cystic Fibrosis (Phase 4)
Diabetes Mellitus (Early Phase 1)
Drug Resistance, Bacterial (Phase 4)
Enterobacteriaceae Infections (Phase 4)
Enterocolitis, Necrotizing (Phase 1/Phase 2)
Escherichia coli Infections (Phase 4)
Febrile Neutropenia (Phase 4)
Fever (Phase 4)
Fibrosis (Phase 2/Phase 3)
Gram-Negative Bacterial Infections (Phase 4)
Healthcare-Associated Pneumonia (Phase 3)
Healthy Volunteers (Phase 4)
Hematologic Neoplasms (Phase 4)
Ileus (Phase 3)
Infections ()
Inflammation (Early Phase 1)
Intestinal Neoplasms (Phase 2)
Intestinal Perforation (Phase 3)
Intraabdominal Infections (Phase 1/Phase 2)
Kidney Diseases (Phase 1)
Klebsiella pneumoniae (Phase 4)
Liver Cirrhosis, Biliary (Phase 4)
Lung Diseases (Phase 3)
Lymphoma (Phase 2)
Melioidosis (Phase 2)
Meningitis (Phase 1/Phase 2)
Neonatal Sepsis (Phase 3)
Neoplasms (Phase 2)
Obesity (Early Phase 1)
Osteomyelitis (Phase 2)
Osteoporosis (Early Phase 1)
Pancreatitis (Phase 4)
Pancreatitis, Acute Necrotizing (Phase 4)
Patient Compliance (Phase 4)
Peritonitis (Phase 3)
Pharmacology (Phase 4)
Pneumonia (Phase 4)
Pneumonia, Bacterial (Phase 2)
Pneumonia, Ventilator-Associated (Phase 4)
Pseudomonas Infections (Phase 4)
Pyelonephritis (Phase 3)
Respiratory Tract Infections (Phase 4)
Rupture (Phase 3)
Sepsis (Phase 4)
Severe Acute Respiratory Syndrome (Phase 1/Phase 2)
Shock, Septic (Phase 4)
Systemic Inflammatory Response Syndrome (Phase 2)
Tuberculosis (Phase 2)
Tuberculosis, Pulmonary (Phase 2)
Typhoid Fever (Phase 4)
Urinary Bladder Neoplasms (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
